Paul Hesketh to Risk Factors
This is a "connection" page, showing publications Paul Hesketh has written about Risk Factors.
Connection Strength
0.210
-
Hesketh PJ, Schnadig ID, Schwartzberg LS, Modiano MR, Jordan K, Arora S, Powers D, Aapro M. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer. 2016 Aug 01; 122(15):2418-25.
Score: 0.061
-
Hesketh PJ, Aapro M, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2010 Sep; 18(9):1171-7.
Score: 0.039
-
Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008 Jun 05; 358(23):2482-94.
Score: 0.035
-
Hesketh PJ, McCoy J, Dunphy FR, Bearden JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara DR. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. J Thorac Oncol. 2006 Nov; 1(9):991-5.
Score: 0.032
-
Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999; 4(3):191-6.
Score: 0.018
-
McKee BJ, Hashim JA, French RJ, McKee AB, Hesketh PJ, Lamb CR, Williamson C, Flacke S, Wald C. Experience with a CT screening program for individuals at high risk for developing lung cancer. J Am Coll Radiol. 2015 Feb; 12(2):192-7.
Score: 0.014
-
Blanchard EM, Moon J, Hesketh PJ, Kelly K, Wozniak AJ, Crowley J, Gandara D. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol. 2011 Jan; 6(1):115-20.
Score: 0.011